Angioplasty

Thromboaspiration in AMI, without benefit to 30 days.

Original title:&nbsp;Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction. TASTE trial.&nbsp;Reference:&nbsp;Ole Fr&ouml;bert et al. N Engl J Med 2013. DOI: 10.1056/NEJMoa1308789 One of the biggest challenges of primary angioplasty is to restore normal coronary flow. Thromboaspiration is a relatively simple, quick and cheap it can improve the flow and resolution of ST , however , the<a href="https://solaci.org/en/2013/09/11/thromboaspiration-in-ami-without-benefit-to-30-days/" title="Read more" >...</a>

Complete revascularization in acute myocardial infarction. 1 culprit lesion , then all the others

Original title:&nbsp;Randomized Trial of Preventive Angioplasty in Myocardial Infarction (PRAMI trial).&nbsp;Referencia:&nbsp;David S. Wald et al. N Engl J Med 2013.DOI: 10.1056/NEJMoa1305520. Patients developing ST segment elevation myocardial infarction are effectively treated with primary angioplasty to responsible artery . It is unclear whether revascularized other significant lesions in other non culprit vessels &nbsp;will prevent future events<a href="https://solaci.org/en/2013/09/09/complete-revascularization-in-acute-myocardial-infarction-1-culprit-lesion-then-all-the-others/" title="Read more" >...</a>

2nd generation drug-eluting stents intended for left main coronary artery

Original title:&nbsp;Zotarolimus- versus Everolimus-Eluting Stents for Unprotected Left Main Coronary Artery Disease. ISAR-LEFT MAIN 2 Study.&nbsp;Reference:&nbsp;Julinda Mehilli et al. J Am Coll Cardiol, article in press. Improvements in 2nd generation drug-eluting stents led to increased efficiency and safety , however there is little information on these new platforms to treat left main coronary artery .<a href="https://solaci.org/en/2013/08/29/2nd-generation-drug-eluting-stents-intended-for-left-main-coronary-artery/" title="Read more" >...</a>

Rivaroxaban reduces in-stent thrombosis in patients with acute coronary syndromes

Original title:&nbsp;Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51.&nbsp;Reference:&nbsp;C. Michael Gibson et al. J Am Coll Cardiol 2013;62:286&ndash;90. There are few contemporary studies that investigated oral anticoagulation utility in patients with acute coronary syndromes and coronary angioplasty. Rivaroxaban is an oral anticoagulant that directly and<a href="https://solaci.org/en/2013/08/23/rivaroxaban-reduces-in-stent-thrombosis-in-patients-with-acute-coronary-syndromes/" title="Read more" >...</a>

Full conversion from transfemoral to transradial: similar success rate and far less complications.

Original title:&nbsp;Full conversion from transfemoral to transradial approach for percutaneous coronary interventions results in a similar success rate and a rapid reduction of in-hospital cardiac and vascular major events.&nbsp;Reference:&nbsp;Vincent Dangoisse et al. EuroIntervention 2013;9:345-352. &nbsp; Although the transfemoral approach has clear disadvantages when it comes to bleeding complications, it continues to be the preferred approach<a href="https://solaci.org/en/2013/08/21/full-conversion-from-transfemoral-to-transradial-similar-success-rate-and-far-less-complications/" title="Read more" >...</a>

Transradial access plus bivalirudin, the best combination to reduce bleeding

Original title:&nbsp;Comparison of bivalirudin and radial access across a spectrum of preprocedural risk of bleeding in percutaneous coronary intervention: Analysis from the National Cardiovascular Data Registry.&nbsp;Reference:&nbsp;Baklanov DV et al. Circ Cardiovasc Interv. 2013, article in press. Bleeding complications are clearly associated to mortality increase and two of the current best strategies to reduce bleeding are<a href="https://solaci.org/en/2013/08/15/transradial-access-plus-bivalirudin-the-best-combination-to-reduce-bleeding/" title="Read more" >...</a>

Multislice computed tomography for bioresorbable scaffolds: the end of invasive diagnostic studies?

Original title:&nbsp;Multislice Computed Tomography Angiography for Non-invasive Assessment of the 18-Months Performance of a Novel Radiolucent Bioresorbable Vascular Scaffolding Device (ABSORB Trial).&nbsp;Reference:&nbsp;Koen Nieman et al. J Am Coll Cardiol, article in press. Metal stents revolutionized coronary angioplasty procedures; however, they are permanent prosthetic devices that make re intervention difficult and prolongue thrombosis risk. This problem<a href="https://solaci.org/en/2013/08/14/multislice-computed-tomography-for-bioresorbable-scaffolds-the-end-of-invasive-diagnostic-studies/" title="Read more" >...</a>

High doses of radiation also in peripheral procedures

Original title:&nbsp;Patient radiation exposure during percutaneous endovascular revascularization of the lower extremity.&nbsp;Reference:&nbsp;Einat Segal et al. Journal of Vascular Surgery. Article in press. Percutaneous endovascular revascularization is emerging as the first line treatment for peripheral artery disease for both intermittent claudication and chronic critical limb ischemia. Radiation doses for these interventions, usually prolonged, have not been<a href="https://solaci.org/en/2013/08/12/high-doses-of-radiation-also-in-peripheral-procedures/" title="Read more" >...</a>

Pharmacological stent intimal coverage with overlap versus no overlap

Original title:&nbsp;Tissue coverage and neointimal hyperplasia in overlap versus nonoverlap segments of drug-eluting stents 9 to 13 months after implantation: In vivo assessment with optical coherence tomography.&nbsp;Reference:&nbsp;Juan Luis Guti&eacute;rrez-Chico et al. Am Heart J 2013;166:83-94.e3. The drug-eluting stent&rsquo;s (DES) overlapping effect over neointimal healing is not completely understood. Drug overdose, large amounts of polymer and<a href="https://solaci.org/en/2013/08/05/pharmacological-stent-intimal-coverage-with-overlap-versus-no-overlap/" title="Read more" >...</a>

Ticagrelor similar to clopidogrel in terms of coronary flow and myocardial perfusion

T&iacute;tulo original:&nbsp;Angiographic Outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).&nbsp;Referencia:&nbsp;Vijay Kunadian et al. J Am Coll Cardiol Intv 2013;6:671&ndash;83. In the PLATO (Platelet Inhibition and Patient Outcomes) trial, treatment with ticagrelor compared with clopidogrel resulted in a significant reduction in the combined endpoint of cardiac death, heart attack or stroke in patients undergoing<a href="https://solaci.org/en/2013/07/19/ticagrelor-similar-to-clopidogrel-in-terms-of-coronary-flow-and-myocardial-perfusion/" title="Read more" >...</a>

Top